This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.
|Original language||English (US)|
|Number of pages||6|
|Journal||Oncology (Williston Park, N.Y.)|
|Issue number||11 Suppl 5|
|State||Published - Oct 2007|
ASJC Scopus subject areas
- Cancer Research